Journal of Oncology

Journal of Oncology / 2020 / Article

Research Article | Open Access

Volume 2020 |Article ID 9327512 |

Qiu-ting Li, Meng-jun Qiu, Sheng-li Yang, Xiefan Fang, Xiao-xiao He, Meng-meng Wang, Ya-nan Li, Zhi-fan Xiong, Shanshan Huang, "Alpha-Fetoprotein Regulates the Expression of Immune-Related Proteins through the NF-κB (P65) Pathway in Hepatocellular Carcinoma Cells", Journal of Oncology, vol. 2020, Article ID 9327512, 9 pages, 2020.

Alpha-Fetoprotein Regulates the Expression of Immune-Related Proteins through the NF-κB (P65) Pathway in Hepatocellular Carcinoma Cells

Academic Editor: Da Li
Received13 Sep 2019
Revised19 Jun 2020
Accepted08 Jul 2020
Published28 Jul 2020


Background. The prognosis of patients with hepatocellular carcinoma (HCC) is poor, with 60% to 70% of patients developing recurrence and metastasis within five years of radical resection. Alpha-fetoprotein (AFP) plays a significant role in predicting the recurrence and metastasis of HCC after surgery. However, its role in modulating tumor immunity has not been investigated. Our objective was to examine the effect of AFP on the expression of B7 family and activation of the NF-κB (P65) pathway in HCC. Methods. We generated human hepatoma SMMC-7721 cell lines with or without recombinant AFP transfection (AFPup and control groups). Colony formation assay, Transwell invasion assay, and wound healing assay were used to detect the function of AFP. Liver cancer xenografts were made in BALB/c nude male mice (N = 6 per group). After 28 days of inoculation, the expression of immune genes in the HCC tissues, including PD-L (B7-H1), B7-H3, B7-H4, and P65, was evaluated by quantitative real-time PCR (qPCR) and western blot. In addition, immunofluorescence was used to determine the subcellular localization of the P65 protein, a key factor in the NF-κB pathway. An online HCC patients’ dataset was also used to detect the connection between AFP and P65. Results. Overexpression of AFP could enhance proliferation, invasion, and migration of HCC cells. Both qPCR and western blot results demonstrated that the expressions of PD-L1, B7-H4, and P65 were significantly higher in the AFP group compared to the controls (). Immunofluorescence results indicated that the majority of the P65 protein was located in the cytoplasm in the control group but was translocated to the nucleus in the AFPup group. The Spearman correlation coefficient confirms that AFP has a positive correlation with P65 in HCC patients (R = 0.33, ). Conclusion. AFP could enhance proliferation, invasion, and migration in HCC cells. The upregulation of AFP would increase the PD-L1 and B7-H4 mRNA and protein expression in HCC tissues through the upregulation and activation of the P65 protein.

1. Introduction

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer-related deaths in the world. Its etiology is largely unknown, and it is prone to early metastasis and infiltration to adjacent and distant tissues [1, 2]. Alpha-fetoprotein (AFP) is one of the major proteins in the serum of vertebrate embryos and is highly expressed in HCC. According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology 2019, patients are suspected to develop HCC when they have a serum AFP level > 100 ng/mL or AFP level increases by ≥ 7 ng/mL/month in at least 3 tests. A positive AFP level should prompt computed tomography (CT) or magnetic resonance imaging (MRI) exams regardless of the ultrasonography (US) results [3, 4]. Using the AFP level detection, HCC is the only solid tumor that can be diagnosed by a blood test. AFP has been used as a tumor marker of HCC and plays an essential role in liver cancer screening, diagnosis, monitoring, and prognosis prediction, but its biological functions are still poorly understood [5, 6].

Conventional treatments for cancers include surgery, chemotherapy, and radiotherapy. Immunotherapy and targeted therapy have been gradually introduced to the clinic and recently recognized as the most promising treatment to cure malignant tumors. The healthy immune system detects and clears tumor cells, which is regulated by a large number of immune activators and inhibitors [7]. Tumor cells can express critical regulatory markers of immune checkpoints, such as PD-L1, B7-H3, and B7-H4, to inhibit the body’s antitumor immune response and promote tumor immune escape [8].

As AFP is highly expressed in HCC tissues, its involvement in the tumor immune escape mechanisms remains unexplored. In this study, we investigated the effects of AFP on immune-related protein expression and NF-κB pathway (P65) activation, which elucidated the molecular association between AFP expression and tumor immunity.

2. Methods

All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee of Tongji Medical College (Wuhan, China).

2.1. Cell Line and Cell Culture

The human HCC cell line SMMC-7721 was obtained from the Chinese Center for Type Culture Collection (CCTCC, Wuhan, China). The cell line was cultured in DMEM (Life Technologies, Beijing, China) supplemented with 10% fetal bovine serum (FBS) (Life Technologies) and maintained at 37°C in a humidified atmosphere with 5% CO2.

2.2. Genetic Overexpression

The recombinant AFP and negative control lentiviruses were purchased from Shanghai Jikai Genetic Company (Shanghai, China). A single-cell suspension of SMMC-7721 cells was prepared and adjusted to a cell density of 1105/ml. The suspension (1 ml/well) was inoculated into a 6-well plate, with n = 3 wells per treatment. After reaching approximately 40% cell confluency, the recombinant AFP or negative control lentiviruses were transfected into the SMMC-7721 cells.

2.3. Colony Formation Assay

500 per well of HCC cells from the AFP and control groups were seeded in 6-well plates, respectively. The medium was changed every 3 days. After 10 days, 4% paraformaldehyde (Servicebio, Wuhan, China) was used to fix colonies and 1% crystal violet (Bikeman, Changde, China) was used to stain colonies.

2.4. Wound Healing Assay

AFP and control group cells were seeded in 6-well plates with the number of 1 × 106 cells per well. 200 μl plastic pipette tip was used to create wounds for each group and the medium was changed into serum-free medium. Pictures were taken at 0 h, 24 h, and 48 h to measure the migration rate.

2.5. Transwell Invasion Assay

Transwell cell culture inserts and BD Matrigel were bought from Corning Costar Corporation (Corning, USA). Both AFP and control groups were seeded in Transwell cell culture inserts 10^4 per well with serum-free medium, respectively. The lower chambers were filled with the medium mixed with 20% FBS. 48 h later, cotton swabs were used to clean the cells in the upper surface of the upper chambers. Then, chambers were fixed by 4% paraformaldehyde. 1% crystal violet was used to stain after cells in inserts were fixed. Microscopy was used to count the cells and invasive cells were photographed.

2.6. Animal Experiments

SMMC-7721 cells transfected with recombinant AFP or negative control lentiviruses were collected at the exponential phase, processed to cell suspensions, and subcutaneously injected (0.2 ml; 5 × 106 cells) into the right axilla of BALB/c nude male mice (N = 6 per group). The longest (A) and shortest (B) diameters of the tumor were measured every 4 days with a Vernier caliper. The tumor volume was calculated according to the following formula: V (mm3) = AB2/2. The tumor growth curve was plotted to compare the growth rate of the subcutaneous liver cancer xenografts with or without AFP overexpression. After 28 days of inoculation, the mice were euthanized to isolate the tumors.

2.7. qPCR Assay

Total RNA was extracted from the HCC tumor tissues transfected with recombinant AFP or negative control lentiviruses. cDNA was prepared with a PrimeScript® RT Reagent Kit (Takara, Japan). qPCR was performed with a SYBR ®Premix Ex Taq kit (Takara, Japan) on a LightCycler ® 480 system (Roche Diagnostics), according to the manufacturer’s protocol. The expression of the target genes was determined by the relative quantitation value against GAPDH expression. The primer sequences are shown in Table 1.

GeneOligonucleotide sequence


2.8. Western Blot Analysis

Western blot was done as previously described [9]. Primary antibodies against AFP, B7-H3, B7-H4, PD-L1 (B7-H1), and P65 were bought from Proteintech (Wuhan, China), and GAPDH was made by Abcam (Cambridge, MA, USA).

2.9. Immunofluorescence

Cells isolated from the HCC xenografts transfected with or without AFP were seeded onto 24-well plates and allowed to attach. Next, 4% paraformaldehyde was added for 15 minutes to immobilize cells. After washing 3 times with PBS, 0.25% Triton X was added for 15 minutes on ice to improve the permeability of the cytomembrane. The plate was washed 3 times more with PBS before the addition of goat serum for 30 minutes at room temperature for blocking. After rinsing with PBS, the cells were incubated with the anti-P65 (1 : 50) antibody at 4°C overnight. The primary antibody was removed, and the plate was washed 3 times with PBS. Samples were then incubated with a Cy3-conjugated secondary antibody for 1 hour at room temperature. After washing with PBS, the cellular nuclei were stained with DAPI for 15 minutes at room temperature. High-magnification fluorescent images were obtained using an inverted epifluorescence microscope (Nikon, Japan). The localization of P65 expression was analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

2.10. Clinical Data

Clinical samples were obtained from a HCC proteomic research [10]. The research collected 35 patients’ HCC tissues and used proteomic and phosphoproteomic profiling to characterize their gene expressions. This article was published in Nature in 2019, and its data had been uploaded to a data portal at Researchers could access these data from this open-source online dataset. We used these data to explore the connection between AFP and P65.

2.11. Statistical Analysis

Statistical analysis was performed with SPSS® version 23.0. T test was used to compare differences between groups. The correlation between AFP and P65 was analyzed using the Spearman test. Differences with was considered as statistically significant.

3. Results

3.1. AFP Accelerates HCC Cell Proliferation In Vitro

The colony formation assay results showed that the upregulation of AFP in HCC cells could enhance its ability of proliferation (Figure 1). Colonies in the AFPup group were significantly larger and more than the control group ().

3.2. AFP Could Enhance Invasion and Migration of HCC Cell Line

In wound healing assay, the migration rate in the AFPup group is higher than that in the control group at 24 h and 48 h () (Figures 2(a) and 2(c)). Transwell results showed that more invasion cells could be observed in the AFPup group () (Figures 2(b) and 2(d)). From these results, we have found that upregulation of AFP could enhance the invasion and migration of HCC cells.

3.3. AFP Promotes HCC Xenograft Growth in the Nude Mouse Model

The rate of tumor-bearing was 100% in the mice inoculated with the SMMC-7721 cells, and none of the tumor-bearing mice died during the experiment. The growth of the tumor volume was significantly faster in the AFP group compared to the controls. After 28 days of inoculation, the volumes of dissociated xenografts were 1580.50 ± 420.99 mm3 and 1085.77 ± 365.35 mm3 for the AFP and control groups () (Figure 3(a). The weight of the xenografts in the AFP group is 1.63 ± 0.34 g, while that in the control group is 1.14 ± 0.41 g () (Figure 3(b)). The xenografts in the AFP group were significantly larger and heavier compared to controls ().

3.4. Overexpression of AFP Increases the mRNA and Protein Expression of B7-H4 and PD-L1

qPCR results showed that the mRNA expression of PD-L1 and B7-H4 was significantly higher in the AFP group compared to controls (; Figure 4). Consistently, western blot analysis also indicated higher PD-L1 and B7-H4 protein expression in the AFP group than controls (Figure 5). There were no differences in B7-H3 mRNA or protein expression between the AFP and control groups.

3.5. AFP Enhances the Expression and Nucleus Translocation of P65

Both the qPCR and western blot results showed that the expression of P65, a key protein in the NF-κB pathway, was increased in the AFP group compared to controls (Figures 4 and 5). Immunofluorescence analysis revealed that the majority of the P65 protein was located in the cytoplasm in the control group but was translocated to the nucleus in the AFP group (Figure 6).

3.6. AFP Has a Positive Correlation with P65 in HCC Patients

We used open-source online data to test the correlation between AFP and P65. 35 HCC patients were included in the dataset [10]. P65 showed a positive correlation with AFP (R = 0.33, ) in HCC patients (Figure 7).

4. Discussion

At present, immunotherapies targeting immune checkpoints offer promising treatment options for many cancers. T cells are the major immune cell population to fight tumor cells, and their activation is regulated by the innate immune system through positive and negative costimulatory molecules [11]. The B7/CD28 family plays a crucial role in the regulation of T-cell responses by providing costimulatory and coinhibitory signals [12, 13]. Nine members of the B7 family have been documented in the NCBI, and they play important roles in the regulation of the adaptive immune system using Ig/TCR/MHC [14]. According to previous reports, the B7 family is associated with HCC aggressiveness, leading to a poor prognosis [1519]. Some reports have confirmed that the differential expression of PD-L1 (B7-H1) in HCC patients may lead to different prognosis outcomes, and inhibition of the PD-L1 immunomodulatory pathways may contribute to antitumor effects in HCC [2022]. B7-H3 triggers inhibitory signals in effector T cells and promotes the progression of hepatitis B virus (HBV) infection, which may lead to the development of HCC [23]. B7-H4 is believed to be involved in the pathogenesis, recurrence, and antitumor immunity of HCC [24, 25], and overexpression of B7-H4 may cause poor overall survival in HCC patients [26].

AFP is mainly present in embryonic hepatocytes, whereas its expression is almost undetectable after adulthood. However, AFP is elevated in almost all liver cancer patients. A large number of clinical studies have reported that HCC patients with high AFP mRNA and/or protein levels in the blood have higher metastasis and postoperative recurrence rates than patients with low AFP levels [27, 28]. In our study, upregulation of AFP could heighten proliferation, invasion, and migration of HCC cells in vitro. Our current study also revealed that AFP increased the expression of PD-L1 and B7-H4, which may enhance the immune checkpoint function and inhibit the antitumor immune response, leading to immune escape. In order to find out the interaction network between AFP and B7 family, we search the PubMed for more information. During our reading, we found an article, which had introduced transcription factors that bound around PD-L1 [29]. After reading more articles, we suggest that P65 may be a factor to control PD-L1 expression [3033]. Thus, we choose P65 as an object of our study.

P65, also known as Rel-A, is one of the most important proteins in the NF-κB pathway [34]. P65 regulates transcriptional activities and promotes the binding of P50 and DNA [35, 36]. Under normal conditions, NF-κB-related proteins are sequestered within the cytoplasm through direct interactions with the inhibitor proteins. Upon activation, P65 and P50 form a heterodimer and translocate to the nucleus, recruit transcription coactivators, bind to the target DNA elements, and activate the transcription of downstream genes [37,38]. In our study, immunofluorescence results showed that with high AFP expression, the P65 protein was translocated to the nucleus, indicating that the NF-κB pathway was activated in the AFP group. qPCR and western blot analyses revealed the upregulation of P65, as well as PD-L1 and B7-H3, in the AFP group. It suggested that upregulation of PD-L1 and B7-H3 by AFP was mediated by the activation of the NK-κB (P65) pathway in HCC cells. By using online dataset, we also confirmed that the expression of P65 has a positive correlation with the level of AFP in HCC patients.

In conclusion, our results demonstrated that AFP could enhance proliferation, invasion, and migration of HCC cells. It also has the ability to increase the expression of PD-L1 and B7-H4 in HCC xenografts inoculated in nude mice, possibly via activation of the NF-κB (P65) pathway. Therefore, AFP may promote tumor immune escape, leading to HCC tumor growth, metastasis, and recurrence.


HCC:Hepatocellular carcinoma
PCR:Polymerase chain reaction
NCCN:National Comprehensive Cancer Network
FBS:Fetal bovine serum
BSA:Bovine serum albumin.

Data Availability

All data generated or analyzed in this study are included in the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Qiu-ting Li and Meng-jun Qiu contributed equally to this work.


The authors thank the Institute of Biomedical Research Lab and Division of Gastroenterology of Taihe Hospital for lending them a place to revise their work. The authors are grateful for their kindness and unselfish help when they have problems in revising their work. This study was supported by the National Key Research and Development Program of China (2018YFC2002000), the Henry research fund for hepatobiliary and pancreatic malignancies of Chen Xiao-ping foundation for the Development of Science and Technology of Hubei Province (CXPJJH11800001-2018317), and the Fundamental Research Funds for the Central Universities: the Independent Innovation Fund of Huazhong University of Science and Technology (no. 2018KFYYXJJ106).


  1. A. Forner, J. M. Llovet, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 379, no. 9822, pp. 1245–1255, 2012. View at: Publisher Site | Google Scholar
  2. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at: Publisher Site | Google Scholar
  3. E. Waidely, A.-R. O. Al-Yuobi, A. S. Bashammakh, M. S. El-Shahawi, and R. M. Leblanc, “Serum protein biomarkers relevant to hepatocellular carcinoma and their detection,” The Analyst, vol. 141, no. 1, pp. 36–44, 2016. View at: Publisher Site | Google Scholar
  4. O. Arrieta, B. Cacho, D. Morales-Espinosa, A. Ruelas-Villavicencio, D. Flores-Estrada, and N. Hernandez-Pedro, “The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis,” BMC Cancer, vol. 7, p. 28, 2007. View at: Publisher Site | Google Scholar
  5. J. H. Schieving, M. de Vries, J. M. G. van Vugt et al., “Alpha-fetoprotein, a fascinating protein and biomarker in neurology,” European Journal of Paediatric Neurology, vol. 18, no. 3, pp. 243–248, 2014. View at: Publisher Site | Google Scholar
  6. R. J. Wong, A. Ahmed, and R. G. Gish, “Elevated alpha-fetoprotein,” Clinics in Liver Disease, vol. 19, no. 2, pp. 309–323, 2015. View at: Publisher Site | Google Scholar
  7. G. L. Beatty and W. L. Gladney, “Immune escape mechanisms as a guide for cancer immunotherapy,” Clinical Cancer Research, vol. 21, no. 4, pp. 687–692, 2015. View at: Publisher Site | Google Scholar
  8. S. L. Topalian, C. G. Drake, and D. M. Pardoll, “Immune checkpoint blockade: a common denominator approach to cancer therapy,” Cancer Cell, vol. 27, no. 4, pp. 450–461, 2015. View at: Publisher Site | Google Scholar
  9. M. Tong, N. Che, L. Zhou et al., “Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib,” Journal of Hepatology, vol. 69, no. 4, pp. 826–839, 2018. View at: Publisher Site | Google Scholar
  10. Y. Jiang, A. Sun, A. Sun et al., “Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma,” Nature, vol. 567, no. 7747, pp. 257–261, 2019. View at: Publisher Site | Google Scholar
  11. L. Ni and C. Dong, “New B7 family checkpoints in human cancers,” Molecular Cancer Therapeutics, vol. 16, no. 7, pp. 1203–1211, 2017. View at: Publisher Site | Google Scholar
  12. R. J. Greenwald, G. J. Freeman, and A. H. Sharpe, “The B7 family revisited,” Annual Review of Immunology, vol. 23, no. 1, pp. 515–548, 2005. View at: Publisher Site | Google Scholar
  13. X. Zang and J. P. Allison, “The B7 family and cancer therapy: costimulation and coinhibition,” Clinical Cancer Research, vol. 13, no. 18, pp. 5271–5279, 2007. View at: Publisher Site | Google Scholar
  14. M. F. Flajnik, T. Tlapakova, M. F. Criscitiello, V. Krylov, and Y. Ohta, “Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7’s historical relationship with the MHC,” Immunogenetics, vol. 64, no. 8, pp. 571–590, 2012. View at: Publisher Site | Google Scholar
  15. Q. Gao, X.-Y. Wang, S.-J. Qiu et al., “Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma,” Clinical Cancer Research, vol. 15, no. 3, pp. 971–979, 2009. View at: Publisher Site | Google Scholar
  16. Y. Zheng, N. Liao, Y. Wu et al., “High expression of B7H2 or B7H3 is associated with poor prognosis in hepatocellular carcinoma,” Molecular Medicine Reports, vol. 19, pp. 4315–4325, 2019. View at: Google Scholar
  17. T. Liu, Y. Huo, G. Li, G. Yu, and X. Luan, “A negative correlation between B7-H3 expression and the number of CD8+ T cell infiltration in primary hepatocellular carcinoma tissues, Xi bao yu fen zi mian yi xue,” Chinese Journal of Cellular and Molecular Immunology, vol. 30, pp. 1291–1294, 2014. View at: Google Scholar
  18. F. B. Kang, L. Wang, H. C. Jia et al., “B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway,” Cancer Cell International, vol. 15, p. 45, 2015. View at: Publisher Site | Google Scholar
  19. F. Wang, G. Wang, T. Liu, G. Yu, G. Zhang, and X. Luan, “B7-H3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression,” Cancer Investigation, vol. 32, no. 6, pp. 262–271, 2014. View at: Publisher Site | Google Scholar
  20. C. Ihling, B. Naughton, Y. Zhang et al., “Observational study of PD-L1, TGF-beta, and immune cell infiltrates in hepatocellular carcinoma,” Frontiers in Medicine, vol. 6, p. 15, 2019. View at: Publisher Site | Google Scholar
  21. T. Mocan, Z. Sparchez, R. Craciun, C. N. Bora, and D. C. Leucuta, “Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives,” Clinical and Translational Oncology, vol. 21, no. 6, pp. 702–712, 2019. View at: Publisher Site | Google Scholar
  22. Q. Xie, Z. Chen, L. Xia, Q. Zhao, H. Yu, and Z. Yang, “Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population,” Gene, vol. 674, pp. 188–194, 2018. View at: Publisher Site | Google Scholar
  23. F. Gao, J. C. Xu, L. Zhu et al., “Clinical significance of B7-H3 expression during the progression of hepatitis B virus infection,” Viral immunology, vol. 10, 2018. View at: Google Scholar
  24. F.-B. Kang, L. Wang, D.-X. Sun et al., “B7-H4 overexpression is essential for early hepatocellular carcinoma progression and recurrence,” Oncotarget, vol. 8, no. 46, pp. 80878–80888, 2017. View at: Publisher Site | Google Scholar
  25. B. Hong, Y. Qian, H. Zhang et al., “Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 22, no. 18, pp. 4538–4546, 2016. View at: Publisher Site | Google Scholar
  26. S. A. Zhang, Z. X. Wu, X. Zhang, Z. Y. Zeng, and D. L. Li, “Circulating B7-H4 in serum predicts prognosis in patients with hepatocellular carcinoma,” Genetics and Molecular Research, vol. 14, no. 4, pp. 13041–13048, 2015. View at: Publisher Site | Google Scholar
  27. M. Shi, Y. Zhang, C. Zhong, X. J. Lin, C. Q. Zhang, and J. Q. Li, “Correlation of perioperative alpha-fetoprotein expression in peripheral blood to recurrence of hepatocellular carcinoma,” Chinese Journal of Cancer, vol. 27, pp. 83–87, 2008. View at: Google Scholar
  28. K. Han, G. N. Tzimas, J. S. Barkun et al., “Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation,” Canadian Journal of Gastroenterology, vol. 21, no. 1, pp. 39–45, 2007. View at: Publisher Site | Google Scholar
  29. K.-R. Zhou, S. Liu, W.-J. Sun et al., “ChIPBase v2.0: decoding transcriptional regulatory networks of non-coding RNAs and protein-coding genes from ChIP-seq data,” Nucleic Acids Research, vol. 45, no. D1, pp. D43–D50, 2017. View at: Publisher Site | Google Scholar
  30. S. Chen, G. A. Crabill, T. S. Pritchard et al., “Mechanisms regulating PD-L1 expression on tumor and immune cells,” Journal for Immunotherapy of Cancer, vol. 7, p. 305, 2019. View at: Publisher Site | Google Scholar
  31. H. Li, J.-Q. Xia, F.-S. Zhu et al., “LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation,” Journal of Cellular Biochemistry, vol. 119, no. 12, pp. 9997–10004, 2018. View at: Publisher Site | Google Scholar
  32. Z. Zong, J. Zou, R. Mao et al., “M1 macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1β signaling,” Frontiers in Immunology, vol. 10, p. 1643, 2019. View at: Publisher Site | Google Scholar
  33. J. Lucas, T. C. Hsieh, H. D. Halicka, Z. Darzynkiewicz, and J. M. Wu, “Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF-κB signaling,” International Journal of Oncology, vol. 53, pp. 1469–1480, 2018. View at: Google Scholar
  34. F. Le, J.-Y. Zhang, W. Liu, X.-M. Huang, and W.-Z. Luo, “The levels of NF-κB p50 and NF-κB p65 play a role in thyroid carcinoma malignancy in vivo,” Journal of International Medical Research, vol. 46, no. 10, pp. 4092–4099, 2018. View at: Publisher Site | Google Scholar
  35. C. Porta, A. Ippolito, F. M. Consonni et al., “Protumor steering of cancer inflammation by p50 NF-κB enhances colorectal cancer progression,” Cancer Immunology Research, vol. 6, no. 5, pp. 578–593, 2018. View at: Publisher Site | Google Scholar
  36. Y. Z. Li and P. Zhao, “Expressions and clinicopathologic significance of Id2 and NF-kappaB/P65 in gastric cancer,” Zhonghua Yi Xue Za Zhi, vol. 98, pp. 846–850, 2018. View at: Google Scholar
  37. M. S. Hayden and S. Ghosh, “NF-B, the first quarter-century: remarkable progress and outstanding questions,” Genes & Development, vol. 26, no. 3, pp. 203–234, 2012. View at: Publisher Site | Google Scholar
  38. H. Shi and E. A. Berger, “Characterization of site-specific phosphorylation of NF-kappaB p65 in retinal cells in response to high glucose and cytokine polarization,” Mediators of Inflammation, vol. 2018, Article ID 3020675, 15 pages, 2018. View at: Publisher Site | Google Scholar

Copyright © 2020 Qiu-ting Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.